{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang C"],"funding":["Nanchong City University Science and Technology Strategic Cooperation Special Fund","the scientific research foundation for advanced talents, Affiliated hospital of North Sichuan Medical College"],"pagination":["288"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11529151"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["<h4>Background</h4>The current treatment strategies for borderline resectable esophageal squamous cell carcinoma remain controversial. This study aimed to evaluate the efficacy and safety of programmed cell death 1 inhibitors combined with chemotherapy, followed by conversion surgery, for borderline resectable esophageal squamous cell carcinoma.<h4>Methods</h4>Patients with borderline resectable esophageal squamous cell carcinoma treated with induction immunochemotherapy from January 1, 2020 to July 1, 2023 at our hospital were retrospectively analyzed. The primary study outcome was the R0 resection rate. Secondary study outcomes included progression-free survival (PFS), overall survival (OS), pathological complete remission (pCR) rate, and safety.<h4>Results</h4>Forty patients with border"],"journal":["World journal of surgical oncology"],"pubmed_title":["Clinical outcomes of conversion surgery after induction immunochemotherapy for borderline resectable T4 esophageal squamous cell carcinoma."],"pmcid":["PMC11529151"],"funding_grant_id":["2023GC006","22SXQT0095"],"pubmed_authors":["Xu B","Zhang Y","Shi G","Zhang L","Zhang C","Fu M","Luo T"],"additional_accession":[]},"is_claimable":false,"name":"Clinical outcomes of conversion surgery after induction immunochemotherapy for borderline resectable T4 esophageal squamous cell carcinoma.","description":"<h4>Background</h4>The current treatment strategies for borderline resectable esophageal squamous cell carcinoma remain controversial. This study aimed to evaluate the efficacy and safety of programmed cell death 1 inhibitors combined with chemotherapy, followed by conversion surgery, for borderline resectable esophageal squamous cell carcinoma.<h4>Methods</h4>Patients with borderline resectable esophageal squamous cell carcinoma treated with induction immunochemotherapy from January 1, 2020 to July 1, 2023 at our hospital were retrospectively analyzed. The primary study outcome was the R0 resection rate. Secondary study outcomes included progression-free survival (PFS), overall survival (OS), pathological complete remission (pCR) rate, and safety.<h4>Results</h4>Forty patients with border","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-16T07:21:13.469Z","creation":"2025-04-04T01:58:37.171Z"},"accession":"S-EPMC11529151","cross_references":{"pubmed":["39482690"],"doi":["10.1186/s12957-024-03570-8"]}}